tradingkey.logo
tradingkey.logo
Pesquisar

COSCIENS Biopharma Inc

CSCI
Adicionar à lista de desejos
2.720USD
0.0000.00%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
8.64MValor de mercado
PerdaP/L TTM

Mais detalhes de COSCIENS Biopharma Inc Empresa

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

Informações de COSCIENS Biopharma Inc

Código da empresaCSCI
Nome da EmpresaCOSCIENS Biopharma Inc
Data de listagemDec 19, 1995
CEOMs. Anna Biehn
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 19
EndereçoC/O Norton Rose Fulbright Canada Llp
CidadeTORONTO
Bolsa de valoresThe Toronto Stock Exchange
PaísCanada
Código postalM5K 1E7
Telefone18439003201
Sitehttps://www.cosciensbio.com/
Código da empresaCSCI
Data de listagemDec 19, 1995
CEOMs. Anna Biehn

Executivos da empresa COSCIENS Biopharma Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de COSCIENS Biopharma Inc?

Os cinco principais acionistas de COSCIENS Biopharma Inc são: Dr. Ulrich Kosciessa

Quantas instituições possuem ações da COSCIENS Biopharma Inc (CSCI)?

Em 2026Q1, 31 instituições possuíam ações da COSCIENS Biopharma Inc, com valor de mercado aproximado de 257.26K, representando 8.08% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -38426.00.